Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total value of $859,716.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Performance

Shares of UTHR opened at $235.95 on Friday. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $233.36 and a two-hundred day simple moving average of $228.79. The stock has a market cap of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.67 earnings per share. On average, analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Vanguard Group Inc. grew its position in shares of United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after purchasing an additional 20,373 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of United Therapeutics by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock worth $123,566,000 after purchasing an additional 9,962 shares in the last quarter. Norges Bank purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $100,519,000. LSV Asset Management grew its position in shares of United Therapeutics by 1.0% during the third quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company’s stock worth $86,524,000 after purchasing an additional 3,700 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of United Therapeutics by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock worth $70,152,000 after purchasing an additional 7,723 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on UTHR shares. Wells Fargo & Company upped their price target on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. Wedbush reissued an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the company from $213.00 to $215.00 in a report on Monday, February 12th. SVB Leerink began coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.